The European Society of Cardiology (ESC) is preparing to release its 2026 guidelines for heart failure, which will introduce changes to how the condition is classified, according to a report from pharmastar.it.
The Italian pharmaceutical news outlet reported the update on Friday, August 28, 2026, highlighting that the revised framework marks a shift in the current categorization approach used by clinicians.
Per pharmastar.it, the upcoming ESC 2026 guidelines represent a formal update to the society's clinical recommendations for managing heart failure. The new classification system is expected to alter how physicians diagnose and stage the condition, though specific details of the revised categories were not included in the initial report.
The ESC regularly issues comprehensive clinical practice guidelines to standardize care across Europe and beyond. These documents are typically based on the latest evidence and are adopted by national cardiology societies. The 2026 iteration follows previous updates and reflects ongoing research into the pathophysiology and treatment of heart failure, a syndrome affecting millions of patients worldwide.
The report from pharmastar.it did not specify a release date for the full guidelines or outline the exact nature of the classification changes. It also did not mention whether the update will affect treatment algorithms or drug recommendations.
Clinicians and researchers will be watching for the full ESC 2026 document to understand how the new classification will be applied in practice. The complete guidelines are expected to provide clarity on diagnostic criteria and therapeutic strategies, which will likely influence clinical decision-making across Europe in the coming years.
